PmrAB是铜绿假单胞菌的一种双组分调节系统，可调节对阳离子抗菌肽的抗性以及向脂多糖A中添加氨基阿拉伯糖。
PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A.
作者信息
Moskowitz Samuel M, Ernst Robert K, Miller Samuel I
机构信息
Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195, USA.
出版信息
J Bacteriol. 2004 Jan;186(2):575-9. doi: 10.1128/JB.186.2.575-579.2004.
Abstract
Spontaneous polymyxin-resistant mutants of Pseudomonas aeruginosa were isolated. The mutations responsible for this phenotype were mapped to a two-component signal transduction system similar to PmrAB of Salmonella enterica serovar Typhimurium. Lipid A of these mutants contained aminoarabinose, an inducible modification that is associated with polymyxin resistance. Thus, P. aeruginosa possesses a mechanism that induces resistance to cationic antimicrobial peptides in response to environmental conditions.
摘要
分离出了铜绿假单胞菌的自发多粘菌素抗性突变体。导致这种表型的突变被定位到一个与鼠伤寒沙门氏菌血清型鼠伤寒的PmrAB相似的双组分信号转导系统。这些突变体的脂多糖A含有氨基阿拉伯糖，这是一种与多粘菌素抗性相关的可诱导修饰。因此，铜绿假单胞菌拥有一种机制，可根据环境条件诱导对阳离子抗菌肽的抗性。
相似文献
1
PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A.
J Bacteriol. 2004 Jan;186(2):575-9. doi: 10.1128/JB.186.2.575-579.2004.
2
Release of the lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to the antimicrobial peptide polymyxin B in Salmonella enterica.
J Bacteriol. 2007 Jul;189(13):4911-9. doi: 10.1128/JB.00451-07. Epub 2007 May 4.
3
Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.
Mol Microbiol. 2003 Oct;50(1):205-17. doi: 10.1046/j.1365-2958.2003.03673.x.
4
Identification and genetic characterization of PmrA-regulated genes and genes involved in polymyxin B resistance in Salmonella enterica serovar typhimurium.
Infect Immun. 2002 Dec;70(12):6770-8. doi: 10.1128/IAI.70.12.6770-6778.2002.
5
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2009 Dec;53(12):5150-4. doi: 10.1128/AAC.00893-09. Epub 2009 Sep 14.
6
Adaptive and Mutational Responses to Peptide Dendrimer Antimicrobials in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02040-19.
7
Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.
Antimicrob Agents Chemother. 2013 May;57(5):2204-15. doi: 10.1128/AAC.02353-12. Epub 2013 Mar 4.
8
PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients.
Antimicrob Agents Chemother. 2012 Feb;56(2):1019-30. doi: 10.1128/AAC.05829-11. Epub 2011 Nov 21.
9
Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis.
J Biol Chem. 2005 Apr 15;280(15):14765-72. doi: 10.1074/jbc.M413900200. Epub 2005 Feb 14.
10
Molecular basis of Yersinia enterocolitica temperature-dependent resistance to antimicrobial peptides.
J Bacteriol. 2012 Jun;194(12):3173-88. doi: 10.1128/JB.00308-12. Epub 2012 Apr 13.
引用本文的文献
1
Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.
Folia Microbiol (Praha). 2025 Sep 1. doi: 10.1007/s12223-025-01322-z.
2
Amphiphilic nebramine analogs synergize with β-lactam/β-lactamase inhibitor combinations, including cefepime-taniborbactam and meropenem-xeruborbactam against metallo-β-lactamase-carrying .
RSC Med Chem. 2025 Jul 17. doi: 10.1039/d5md00375j.
3
A novel non-catalytic function of PA2803-encoded PcrP contributes to polymyxin B resistance in and redefines the functional role of the PA2803 subfamily.
bioRxiv. 2025 May 13:2025.05.13.653872. doi: 10.1101/2025.05.13.653872.
4
Mutational Analysis of Colistin-Resistant Isolates: From Genomic Background to Antibiotic Resistance.
Pathogens. 2025 Apr 15;14(4):387. doi: 10.3390/pathogens14040387.
5
New Insights into the Mediation of Biofilm Formation by Three Core Extracellular Polysaccharide Biosynthesis Pathways in .
Int J Mol Sci. 2025 Apr 17;26(8):3780. doi: 10.3390/ijms26083780.
6
A biofilm-targeting lipo-peptoid to treat and co-infections.
Biofilm. 2025 Mar 12;9:100272. doi: 10.1016/j.bioflm.2025.100272. eCollection 2025 Jun.
7
Regulation, structure, and activity of the MexXY efflux system.
Antimicrob Agents Chemother. 2025 Apr 7;69(5):e0182524. doi: 10.1128/aac.01825-24.
8
Calprotectin-mediated survival of in coculture with occurs without nutrient metal sequestration.
mBio. 2025 May 14;16(5):e0384624. doi: 10.1128/mbio.03846-24. Epub 2025 Mar 28.
9
Calprotectin elicits aberrant iron starvation responses in under anaerobic conditions.
J Bacteriol. 2025 Apr 17;207(4):e0002925. doi: 10.1128/jb.00029-25. Epub 2025 Mar 26.
10
Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation.
Antibiotics (Basel). 2024 Dec 24;14(1):1. doi: 10.3390/antibiotics14010001.
本文引用的文献
1
Regulation of Salmonella typhimurium virulence gene expression by cationic antimicrobial peptides.
Mol Microbiol. 2003 Oct;50(1):219-30. doi: 10.1046/j.1365-2958.2003.03675.x.
2
Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa.
Mol Microbiol. 2003 Oct;50(1):205-17. doi: 10.1046/j.1365-2958.2003.03673.x.
3
Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37.
Mol Microbiol. 2002 Oct;46(1):157-68. doi: 10.1046/j.1365-2958.2002.03146.x.
4
Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.
Pediatr Pulmonol. 2002 Oct;34(4):257-61. doi: 10.1002/ppul.10166.
5
Toll-like receptors and innate immunity.
Nat Rev Immunol. 2001 Nov;1(2):135-45. doi: 10.1038/35100529.
6
Lipid A modifications in polymyxin-resistant Salmonella typhimurium: PMRA-dependent 4-amino-4-deoxy-L-arabinose, and phosphoethanolamine incorporation.
J Biol Chem. 2001 Nov 16;276(46):43111-21. doi: 10.1074/jbc.M106960200. Epub 2001 Sep 4.
7
Design of Gram-negative selective antimicrobial peptides.
Biochemistry. 2001 May 15;40(19):5777-85. doi: 10.1021/bi0100384.
8
In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Antimicrob Agents Chemother. 2001 Mar;45(3):781-5. doi: 10.1128/AAC.45.3.781-785.2001.
9
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.
J Infect Dis. 2001 Feb 1;183(3):444-52. doi: 10.1086/318075. Epub 2000 Dec 27.
10
Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis.
Ann Pharmacother. 2000 Nov;34(11):1238-42. doi: 10.1345/aph.19370.
Zotero 插件